TickerTalks
Browse all tickers →
TickerTalks›$MREO
MRMREO

Mereo BioPharma Group plc

$MREO·$47M·Biotechnology·Healthcare
$0.27-3.4%YTD-27.2%1Y-84.9%
Mentions · last 7 days
2026-08-27: 4 posts2026-08-28: 4 posts2026-08-29: 2 posts2026-08-30: 0 posts2026-08-31: 3 posts2026-09-01: 1 posts2026-09-02: 1 posts16
Price updated 13h ago·X counts updated 15h ago
MRMREO
$MREOMereo BioPharma Group plc
$0.27-3.43%16 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $MREO, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-09-03

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Mereo BioPharma inks alvelestat deal with Sentynl/Zydus — $40M upfront + up to $435M milestones, Setrusumab milestones from RARE ~$234M.

Mereo BioPharma is a UK-based rare-disease biotech at $0.27 — down 85% TTM but event-ahead on a specific partnership deal plus M&A optionality.

  • The core is pre-revenue: Q1 revenue $0 (as expected), 13% gross margin (limited product revenue), Q1 EPS -$0.042 (Q2 EPS -$0.01 vs -$0.01 est = 0% surprise). FCF yield -54% and ROIC -109% reflect the pre-revenue burn; analysts model 2026 revenue $2.4M and EPS -$0.038. Cash runway extended into late 2027 per the Sentynl deal.
  • The catalyst mix is genuinely fresh: Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency — $40M upfront and R&D milestones plus up to $435M total. Setrusumab milestones from RARE (~$234M) add optionality. Mereo BioPharma Reports Q2 Financial Results and Corporate Highlights.
  • The insider signal is empty: no insider prints in the window either way. Bulls call it 'back over $1.00 quickly' and see M&A optionality with Zydus Lifesciences as the eventual buyer. Some grumble about weak communications from CEO DSK and the $40M upfront being 'a little weak.' Combined with the $234M Setrusumab-related milestones, MREO has a real multi-milestone catalyst stack.

Resolves upward: Nov 9 Q3 print above -$0.01 EPS plus specific Sentynl/Zydus alvelestat regulatory milestone. Deepens the wait: a specific alvelestat clinical setback, or the Zydus/Sentynl option expiring without exercise.

Agrees with X sentimentX is bullish on the alvelestat Sentynl/Zydus deal with $40M upfront + up to $435M milestones plus Setrusumab RARE milestones ~$234M — the mechanics support the event-ahead framing (real deal, real cash runway extended to late 2027, M&A optionality with Zydus). The 'weak communications from CEO DSK' and '$40M upfront a little weak' grumbles are legitimate caveats but don't override the catalyst.

What to watch: November 9 Q3 earnings — EPS above -$0.01 and Sentynl/Zydus alvelestat regulatory milestone. Also specific alvelestat clinical readouts, and Zydus M&A signals.

On the calendar: 2026-11-09 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment28 posts analyzed · as of 2026-08-18

Mereo BioPharma chatter is bullish after a long-awaited alvelestat partnership deal with Sentynl/Zydus: $40M upfront and R&D + up to $435M in milestones, plus Setrusumab milestones from RARE (~$234M) and cash runway extended into late 2027. Bulls call it 'back over $1.00 quickly' and see M&A optionality with Zydus Lifesciences as the eventual buyer. Some grumble about weak communications from CEO DSK and the $40M upfront being 'a little weak,' but the deal-drought is over. Cantor calls FDA dialogue 'ongoing and constructive.'

Read the AI verdict + X sentiment for $MREO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage oncology biotech developing etigilimab (anti-TIGIT antibody) for solid tumors and rare diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $MREO.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $MREO

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+52.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-109%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-75.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-53.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
100.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-81.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
12.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$-0.01$-0.010.0%
Q1 2026May 12, 2026$-0.01$0.02-150.0%
Q4 2025Mar 19, 2026$-0.01$-0.010.0%
Q3 2025Nov 10, 2025$-0.01$-0.01-20.0%
Next earningsMon, Nov 9·consensus EPS $-0.01

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.04$-4.3M
Q4 FY25$0———$-0.05$-7.7M
Q3 FY25$0———$-0.04$-7.3M
Q2 FY25$500K—73.6%-2100%$-0.09$-7.7M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.4M$1.9M – $3.1M-$0.04-$0.10 – $0.044
FY27$20.1M$16.0M – $26.4M-$0.03-$0.10 – $0.035
FY28$11.1M$3.0M – $23.6M-$0.06-$0.07 – -$0.053
FY29$28.8M$23.0M – $37.9M-$0.06-$0.08 – -$0.042
FY30$104.3M$83.1M – $137.1M$0.01$0.01 – $0.011

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.3%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-12.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-54.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 159.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.305-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KListing / delisting noticeAug 198-K — Item 3.01: Listing / delisting notice
AI summary

Mereo BioPharma received a second Nasdaq compliance notice on August 18, 2026 granting an additional 180-day period (until February 16, 2027) to regain compliance with the $1.00 minimum bid price rule, after failing to cure the deficiency during the initial 180-day period ending August 17, 2026. Compliance would require the ADS closing bid price to meet or exceed $1.00 for at least 10 consecutive business days during the extension. If not cured by February 16, 2027, Nasdaq will issue a delisting notice, which Mereo may appeal. This is a material negative indicator — continued sub-$1.00 trading risks delisting and materially restricts MREO's market accessibility.

8-KMaterial agreementAug 118-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

Mereo BioPharma Group (MREO), a UK-based biopharma, entered a material Option and License Agreement with Sentynl Therapeutics granting U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease. On option exercise, Mereo is eligible to receive $40 million in upfront and R&D payments plus up to $435 million in potential milestone payments, along with double-digit tiered royalties on U.S. sales. Mereo retains responsibility for leading the global Phase 3 study and regulatory interactions until study completion. This deal provides Mereo significant non-dilutive capital and validation of alvelestat commercial potential in a rare lung disease with limited treatment options.

8-KShareholder voteMay 148-K — Item 5.07: Shareholder vote
AI summary

MREO (MREO) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on ratification of the independent auditor. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

8-KAcquisition completedMay 128-K — Item 2.01: Acquisition completed
AI summary

MREO (MREO) disclosed its addition to Nasdaq Stock Market LLC Ordinary Shares under 8-K Item 8.01 (other events). Index inclusions are significant because they trigger automatic buying from passive index funds and ETFs that track the benchmark, often resulting in increased share price and trading volume. Index providers typically announce additions in advance of the effective rebalancing date, giving institutions time to adjust their holdings. The event increases MREO's institutional ownership base and enhances its market visibility and liquidity profile.

8-KOfficer or director changeMar 278-K — Item 5.02: Officer or director change
+ 12 other (3 13Gs · 3 earnings 8-Ks · 2 10-Qs · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlightsglobenewswire.com·23d agoSentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)prnewswire.com·23d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$MRNA$ALT$CELU$NWBO$SLS$AMLX$ABCL
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport